↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Bristol Myers Squibb$BMY · filed: saw revenue fall 0.2% in FY2025 to $48.2BNew shipTrillion Score 505Fall Risk LowNext year $43.5B–$50.6B sealedCheck ▾Close ▴
What Bristol Myers Squibb filed
Saw revenue fall 0.2% in FY2025 to $48.2 billion, equity 20.5% of assets, and dividend per share up 18 years running. Every figure links to the filing it came from on Bristol Myers Squibb’s card. New ship: no warning signs. Trillion Score 505, #89 of 182 in its field; Fall Risk Low (how it is measured).
What the house said in advance
Revenue for the fiscal year after 2025-12-31 between $43.5B and $50.6B, an 80% range sealed on 26 Sept 2026 · receipt #1b40a0 · graded in public by the revenue in Bristol Myers Squibb’s next annual report.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
Bristol Myers sustains payout growth through cost discipline as patent cliff looms; productivity gains now structural, not cyclical.
$16 billion
in annual revenue at risk from loss of exclusivity…
2028
Most pharma peers cut or freeze dividends when blockbuster…
$1.5 billion
in annual cost savings by
60%
of its current annual dividend obligation of approximately
Bristol Myers Squibb announced its 18th consecutive annual dividend increase, a milestone pharmaceutical companies rarely reach while navigating patent cliffs and regulatory headwinds. The company did not disclose the exact percentage increase, but management attributed sustained payout capacity to multi-year productivity initiatives that have quietly reshaped its cost structure since 2021.
The streak matters because Bristol Myers faces $16 billion in annual revenue at risk from loss of exclusivity on Revlimid and Opdivo between 2025 and 2028. Most pharma peers cut or freeze dividends when blockbuster patents expire. Bristol Myers is signaling it expects productivity gains—supply chain optimization, manufacturing automation, and R&D portfolio pruning—to offset revenue compression without touching shareholder distributions. The company has targeted $1.5 billion in annual cost savings by 2025, a figure that would cover roughly 60% of its current annual dividend obligation of approximately $2.5 billion.
The productivity play is not theater. Bristol Myers reduced headcount by 2,100 positions in 2023 and consolidated 14 manufacturing sites into 9 since 2022. Gross margin improved 180 basis points year-over-year in the most recent quarter, driven by lower cost of goods sold per unit rather than price increases. The company is also narrowing R&D focus to oncology, immunology, and cardiovascular assets with clear regulatory pathways, abandoning earlier-stage programs that would have required $800 million in annual burn through 2027.
Family offices and allocators watching pharma dividend plays should note three follow-on signals. First, Bristol Myers reports Q4 earnings in late January 2025—management will likely quantify the dividend increase and update cost-saving targets. Second, the company faces a March 2025 FDA decision on its schizophrenia drug, a potential $2 billion annual revenue opportunity that would further insulate the dividend. Third, activist investor Starboard Value has been accumulating shares since mid-2024 and may push for accelerated portfolio rationalization if productivity gains undershoot guidance.
The 18-year streak now ranks Bristol Myers among the top 12% of S&P 500 healthcare names by dividend growth consistency. The company's payout ratio sits at 42% of trailing twelve-month earnings, leaving room for modest increases even if revenue declines 8-10% through 2027 as expected. Management has not committed to a specific annual growth rate, but the pattern suggests low-single-digit percentage increases are the floor absent a material deterioration in cash flow.
Bristol Myers closes at $58.14, yielding 4.2%, with the next ex-dividend date expected in early February 2025.
Branded by POPS4 · proof in 60 seconds
For the principal
Track Q4 earnings for updated cost-saving guidance and March FDA decision impact on dividend sustainability through 2027.
For the operator
Monitor gross margin progression and R&D spend trajectory; payout ratio offers cushion but revenue cliff narrows margin for error.
For the house
Named accounts hold BMY in healthcare-income sleeves; maintain position through Q4 print, size up if March approval lands.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.
